Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 50 USD -2.61% Market Closed
Market Cap: 101.7B USD

Intrinsic Value

The intrinsic value of one BMY stock under the Base Case scenario is 70.85 USD. Compared to the current market price of 50 USD, Bristol-Myers Squibb Co is Undervalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BMY Intrinsic Value
70.85 USD
Undervaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Bristol-Myers Squibb Co

BMY
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for BMY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Bristol-Myers Squibb Co
NYSE:BMY
US
Pharmaceuticals
Market Cap
100.3B USD
IPO
Jul 5, 1929
US
Pharmaceuticals
Market Cap
100.3B USD
IPO
Jul 5, 1929
Price
$false
EPS
$false
Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Heightened patent-expiration risk and revenue concentration around key drugs like Revlimid and Eliquis could sharply reduce Bristol-Myers Squibb’s cash flows, limiting its ability to fund pipeline development.

Bull Theses

Bristol-Myers Squibb holds a leading position in immuno-oncology with proven blockbusters like Opdivo and Yervoy, providing a strong base of recurring revenue and brand recognition.

Show More Less
How do you feel about BMY?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Bristol-Myers Squibb Co
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bristol-Myers Squibb Co

Current Assets 29.8B
Cash & Short-Term Investments 10.9B
Receivables 14.4B
Other Current Assets 4.5B
Non-Current Assets 62.8B
Long-Term Investments 2.1B
PP&E 8.4B
Intangibles 45B
Other Non-Current Assets 7.4B
Efficiency

Free Cash Flow Analysis
Bristol-Myers Squibb Co

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Bristol-Myers Squibb Co

Revenue
48.3B USD
Cost of Revenue
-11.9B USD
Gross Profit
36.4B USD
Operating Expenses
-24.8B USD
Operating Income
11.5B USD
Other Expenses
-20.5B USD
Net Income
-8.9B USD
Fundamental Scores

BMY Profitability Score
Profitability Due Diligence

Bristol-Myers Squibb Co's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

54/100
Profitability
Score

Bristol-Myers Squibb Co's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

BMY Solvency Score
Solvency Due Diligence

Bristol-Myers Squibb Co's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average Altman Z-Score
Positive Net Debt
36/100
Solvency
Score

Bristol-Myers Squibb Co's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 60.92 USD with a low forecast of 33.43 USD and a high forecast of 73.5 USD.

Lowest
Price Target
33.43 USD
33% Downside
Average
Price Target
60.92 USD
22% Upside
Highest
Price Target
73.5 USD
47% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BMY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BMY Insider Trading
Buy and sell transactions by insiders

BMY News

Other Videos
What is the Intrinsic Value of one BMY stock?

The intrinsic value of one BMY stock under the Base Case scenario is 70.85 USD.

Is BMY stock undervalued or overvalued?

Compared to the current market price of 50 USD, Bristol-Myers Squibb Co is Undervalued by 29%.

Back to Top